FDA Approves Takeda’s EoE Therapy EOHILIA

FDA Approves Takeda’s Groundbreaking Oral Therapy, EOHILIA, as First-line Treatment for Eosinophilic Esophagitis (EoE) in Ages 11 and Older

Takeda Pharmaceutical Company Limited has recently received FDA approval for its groundbreaking oral therapy, EOHILIA, as a first-line treatment for eosinophilic esophagitis (EoE) in individuals aged 11 and older. This approval signifies a major milestone, as EOHILIA becomes the first FDA-approved oral therapy for this chronic immune-mediated disease. The medication is expected to be available to patients by the end of February.